Citadel Advisors
SRNE

Citadel Advisors’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Citadel Advisors’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-823,100
Closed -$729K – 16110
2022
Q4 		$729K Buy
823,100
+348,900
+74% +$463K ﹤0.01% 7457
2022
Q3 		$744K Buy
474,200
+124,200
+35% +$282K ﹤0.01% 7637
2022
Q2 		$704K Sell
350,000
-68,300
-16% -$118K ﹤0.01% 7858
2022
Q1 		$975K Sell
418,300
-530,800
-56% -$1.66M ﹤0.01% 7750
2021
Q4 		$4.41M Buy
949,100
+161,400
+20% +$1M ﹤0.01% 4555
2021
Q3 		$6.01M Sell
787,700
-291,400
-27% -$2.47M ﹤0.01% 3962
2021
Q2 		$10.5M Buy
1,079,100
+202,500
+23% +$1.61M ﹤0.01% 3001
2021
Q1 		$7.25M Sell
876,600
-69,800
-7% -$737K ﹤0.01% 3506
2020
Q4 		$6.46M Sell
946,400
-86,500
-8% -$695K ﹤0.01% 3249
2020
Q3 		$11.5M Buy
1,032,900
+434,100
+72% +$3.97M ﹤0.01% 2126
2020
Q2 		$3.76M Buy
598,800
+450,800
+305% +$1.73M ﹤0.01% 3495
2020
Q1 		$272K Buy
148,000
+85,200
+136% +$245K ﹤0.01% 7503
2019
Q4 		$212K Buy
62,800
+52,600
+516% +$125K ﹤0.01% 8092
2019
Q3 		$22K Buy
+10,200
New +$23.8K ﹤0.01% 8918
2019
Q1 		– Sell
-23,200
Closed -$56K – 10077
2018
Q4 		$56K Sell
23,200
-5,900
-20% -$19.3K ﹤0.01% 8468
2018
Q3 		$128K Sell
29,100
-91,300
-76% -$506K ﹤0.01% 8470
2018
Q2 		$867K Buy
120,400
+106,100
+742% +$722K ﹤0.01% 5468
2018
Q1 		$74K Buy
+14,300
New +$102K ﹤0.01% 7821
2016
Q1 		– Sell
-12,700
Closed -$111K – 8299
2015
Q4 		$111K Buy
12,700
+2,300
+22% +$19.4K ﹤0.01% 6569
2015
Q3 		$87K Buy
10,400
+10,200
+5,100% +$162K ﹤0.01% 7094
2015
Q2 		$4K Sell
200
-1,500
-88% -$19.3K ﹤0.01% 8576
2015
Q1 		$20K Buy
+1,700
New +$19.7K ﹤0.01% 7913

Other funds holding SRNE

PP
Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
OFA
Oaktree Fund Advisors Los Angles, California $56.9M AUM 80.32% 1-Year Est. Return
CGA
Crescent Grove Advisors Lake Forest, Illinois $1.04B AUM 17.78% 1-Year Est. Return
LCM
Lattice Capital Management Kirkland, Washington $56.9M AUM 49.15% 1-Year Est. Return
STB
S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return
GA
GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return
HFRG
Houlihan Financial Resource Group Ashburn, Virginia $257M AUM 14.19% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
GBWM
Granite Bay Wealth Management Portsmouth, New Hampshire $470M AUM 15.4% 1-Year Est. Return

Citadel Advisors's SRNE Position: Q1 2023 in Review

Citadel Advisors sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2023, closing a stake of 200,096 shares — an estimated $177K sold.

Citadel Advisors first reported a position in SRNE in Q1 2015 and held it in 26 quarters. The position peaked at $4.77M in Q1 2021. 34 funds tracked by Wall St. Rank hold SRNE as of Q1 2023.

  • Citadel Advisors reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
  • Citadel Advisors sold 200,096 Sorrento Therapeutics, Inc. shares in Q1 2023, an estimated $177K.
  • Citadel Advisors first reported a position in Sorrento Therapeutics, Inc. in Q1 2015 and held it in 26 quarters.
  • Citadel Advisors's Sorrento Therapeutics, Inc. position peaked at $4.77M in Q1 2021.
  • 34 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2023.

Based on Citadel Advisors's 13F filing for Q1 2023, filed 15 May 2023.